Goldman Sachs’s Pardes Biosciences, Inc. Common Stock PRDS Stock Holding History

Goldman Sachs’s Portfolio PRDS Stock Details PRDS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-838,362	Closed	-$1.52M	–	6016
2023 Q2	$1.52M	Buy	838,362 +22,166	+3%	+$40.5K	﹤0.01%	4066
2023 Q1	$1.08M	Sell	816,196 -1,367,207	-63%	-$2.24M	﹤0.01%	4333
2022 Q4	$3.69M	Sell	2,183,403 -3,646,268	-63%	-$4.62M	﹤0.01%	3449
2022 Q3	$10.8M	Buy	5,829,671 +1,553,757	+36%	+$4.63M	﹤0.01%	2438
2022 Q2	$13.1M	Buy	4,275,914 +2,163,503	+102%	+$13.2M	﹤0.01%	2252
2022 Q1	$15.3M	Buy	+2,112,411	New	+$20.8M	﹤0.01%	2281

Other funds holding PRDS

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

Goldman Sachs's PRDS Position: Q3 2023 in Review

Goldman Sachs sold out of Pardes Biosciences, Inc. Common Stock (PRDS) in Q3 2023, closing a stake of 838,362 shares — an estimated $1.52M sold.

Goldman Sachs first reported a position in PRDS in Q1 2022 and held it in 6 quarters. The position peaked at $15.3M in Q1 2022. 1 fund tracked by Wall St. Rank holds PRDS as of Q3 2023.

Goldman Sachs reported no remaining Pardes Biosciences, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
Goldman Sachs sold 838,362 Pardes Biosciences, Inc. Common Stock shares in Q3 2023, an estimated $1.52M.
Goldman Sachs first reported a position in Pardes Biosciences, Inc. Common Stock in Q1 2022 and held it in 6 quarters.
Goldman Sachs's Pardes Biosciences, Inc. Common Stock position peaked at $15.3M in Q1 2022.
1 fund tracked by Wall St. Rank held Pardes Biosciences, Inc. Common Stock as of Q3 2023.

Based on Goldman Sachs's 13F filing for Q3 2023, filed 14 Nov 2023.